Many users experience reduced appetite and food intake on GLP-1 medications, which means they are also consuming less water from food sources
Persistent and uncontrolled oxidative stress and exacerbating NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome activation during severe COVID-19 disease (Lage et al., 2022), induce production of pro-inflammatory cytokines, such as IL-1 and IL-18, that can be explained because of sharply decreased macrophage GSH intracellular levels associated with increased GSH efflux (Zhang T
Originally developed for type 2 diabetes management, semaglutide demonstrated such powerful weight loss effects in clinical trials that it became the first GLP-1 explicitly approved for chronic weight management in people without diabetes
The benefits of losing significant body fat often outweigh the risks of a small, managed loss of lean mass
The medication works by reducing appetite and increasing the feeling of fullness, leading to reduced food intake and ultimately supporting weight loss efforts